We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · July 13, 2021

T3N2 ER-PR- HER2+ Invasive Ductal Carcinoma of the Left Breast

Written by
Ana C. Sandoval Leon MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • oscar aballay


  • Swapan Kumar   Nath

    I suggest trastuzumab deruxtecan



  • Zuhair ALZIBAIR

    There was a partial response to docetaxel PH initially ...since the goal of the treatment is palliative in principle ,I suggest re-challenge with weekly paclitaxel- trastuzumab pertuzumab

  • Gail Morris

    5 Start with SBRT to liver, then 4, if the patient agrees. I’m speaking as a physician with ER-PR-HER2+ ductal carcinoma with no recurrence of liver mets after 14 years. The word “palliative” is not in my vocabulary. I never comment on forums but feel like I need to weigh in on this one. If even one oncologist reading this considers SBRT in a case such as this, I will be happy.

  • Kavi Capildeo

    3 or 4

  • Barb Stein

    As a RN with Er Pr neg HER2+ with mets to my liver. SBRT to liver mets after 6 rounds of THP followed by H&P (Cleopatra trial). Did the trick for me! 6 years NED on H&P.

  • Barb Stein

    As she had a reoccurrence 3 years out, first line metastatic would be 1 and since oligometastisis SBRT to any residual met.

  • surapong  supaporn

    Ans. 1 : as cleopatra trial : recurrent after 3 years completion of adjuvant therapy :

  • Sep 22, 2021

    Pending Moderator approval.

Further Reading